A logistic regression model for predicting axillary lymph node metastases in early breast carcinoma patients

Sensors (Switzerland)

Volumn 12, Issue 7, 2012, Pages 9936-9950

  Xie, Fei ^a   Yang, Houpu ^a   Wang, Shu ^a   Zhou, Bo ^a   Tong, Fuzhong ^a   Yang, Deqi ^a   Zhang, Jiaqing ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Axillary metastases; Breast cancer; Logistic regression; Lymph node staging; Predictive model

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; KISS1 PROTEIN, HUMAN; KISSPEPTIN;

ARTICLE; BREAST TUMOR; CANCER STAGING; FEMALE; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL;

BREAST NEOPLASMS; FEMALE; HUMANS; KISSPEPTINS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; ROC CURVE;

EID: 84864352591     PISSN: 14248220     EISSN: None     Source Type: Journal    
DOI: 10.3390/s120709936     Document Type: Article

References (49)

1. Soerjomataram, I.; Louwman, M.W.; Ribot, J.G.; Roukema, J.A.; Coebergh, J.W. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res. Treat. 2008, 107, 309-330.
2. Velanovich, V.; Szymanski, W. Quality of life of breast cancer patients with lymphedema. Am. J. Surg. 1999, 177, 184-187.
3. Maunsell, E.; Brisson, J.; Deschenes, L. Arm problems and psychological distress after surgery for breast cancer. Can. J. Surg. 1993, 36, 315-320.
4. Gipponi, M.; Bassetti, C.; Canavese, G.; Catturich, A.; Di Somma, C.; Vecchio, C.; Nicolò, G.; Schenone, F.; Tomei, D.; Cafiero, F. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. J. Surg. Oncol. 2004, 85, 102-111.
5. Gipponi, M.; Bassetti, C.; Canavese, G.; Catturich, A.; di Somma, C.; Vecchio, C.; Nicolò, G.; Schenone, F.; Tomei, D.; Cafiero, F. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery. Ann. Surg. 2007, 245, 452-461.
6. Gipponi, M.; Bassetti, C.; Canavese, G.; Catturich, A.; di Somma, C.; Vecchio, C.; Nicolò, G.; Schenone, F.; Tomei, D.; Cafiero, F. Lymphedema after sentinel lymphadenectomy for breast carcinoma. Cancer 2001, 92, 748-752.
7. Rönkä, R.; von Smitten, K.; Tasmuth, T.; Leidenius, M. One-year morbidity after sentinel node biopsy and breast surgery. Breast 2005, 14, 28-36.
8. Barone, J.E.; Tucker, J.B.; Perez, J.M.; Odom, S.R.; Ghevariya, V. Evidence-based medicine applied to sentinel lymph node biopsy in patients with breast cancer. Am. Surg. 2005, 71, 66-70.
9. Veronesi, U. The sentinel node and breast cancer. Br. J. Surg. 1999, 86, 1-2.
10. Kamath, V.J.; Giuliano, R.; Dauway, E.L.; Cantor, A.; Berman, C.; Ku, N.N.; Cox, C.E.; Reintgen, D.S. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: A study to evaluate the need for complete axillary lymph node dissection. Arch. Surg. 2001, 136, 688-692.
11. Rahusen, F.D.; Torrenga, H.; van Diest, P.J.; Pijpers, R.; van der Wall, E.; Licht, J.; Meijer, S. Predictive factors for metastatic involvement of nonsentinel nodes in patients with breast cancer. Arch. Surg. 2001, 136, 1059-1063.
12. Giuliano, A.E.; Hunt, K.K.; Ballman, K.V.; Beitsch, P.D.; Whitworth, P.W.; Blumencranz, P.W.; Leitch, A.M.; Saha, S.; McCall, L.M.; Morrow, M. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. J. Am. Med. Assoc. 2011, 305, 569-575.
13. Cady, B. Case against axillary lymphadenectomy for most patients with infiltrating breast cancer. J. Surg. Oncol. 1997, 66, 7-10.
14. Van Zee, K.J.; Manasseh, D.M.; Bevilacqua, J.L.; Boolbol, S.K.; Fey, J.V.; Tan, L.K.; Borgen, P.I.; Cody, H.S.; Kattan, M.W. A nomogram for predicting the likelihood of additional nodal metastasis in breast cancer patients with a positive sentinel node biopsy. Ann. Surg. Oncol. 2003, 10, 1140-1151.
15. Barranger, E.; Coutant, C.; Flahault, A.; Delpech, Y.; Darai, E.; Uzan, S. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res. Treat. 2005, 91, 113-119.
16. Pal, A.; Provenzano, E.; Duffy, S.W.; Pinder, S.E.; Purushotham, A.D. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br. J. Surg. 2008, 95, 302-309.
17. Katz, A.; Smith, B.L.; Golshan, M.; Niemierko, A.; Kobayashi, W.; Raad, R.A.; Kelada, A.; Rizk, L.; Wong, J.S.; Bellon, J.R.; et al. Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J. Clin. Oncol. 2008, 26, 2093-2098.
18. Gur, A.S.; Unal, B.; Ozbek, U.; Ozmen, V.; Aydogan, F.; Gokgoz, S.; Gulluoglu, B.M.; Aksaz, E.; Ozbas, S.; Baskan, S.; et al. Validation of breast cancer nomograms for predicting the non-sentinel lymph node metastases after a positive sentinel lymph node biopsy in a multi-center study. Eur. J. Surg. Oncol. 2010, 36, 30-35.
19. Bevilacqua, J.L.; Kattan, M.W.; Fey, J.V.; Cody, H.S.; Borgen, P.I.; van Zee, K.J. Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation. J. Clin. Oncol. 2007, 25, 3670-3679.
20. Harvey, J.M.; Clark, G.M.; Osborne, C.K.; Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999, 17, 1474-1481.
21. Mickey, R.M.; Greenland, S. The impact of confounder selection criteria on effect estimation. Am. J. Epidemiol. 1989, 129, 129-137.
22. Mansel, R.E.; Fallowfield, L.; Kissin, M.; Goyal, A.; Newcombe, R.G.; Dixon, J.M.; Yiangou, C.; Horgan, K.; Bundred, N.; Monypenny, I.; et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC trial. J. Natl. Cancer Inst. 2006, 98, 599-609.
23. Langer, I.; Guller, U.; Berclaz, G.; Koechli, O.R.; Schaer, G.; Fehr, M.K.; Hess, T.; Oertli, D.; Bronz, L.; Schnarwyler, B.; et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: A prospective Swiss multicenter study on 659 patients. Ann. Surg. 2007, 245, 452-461.
24. Krag, D.N.; Julian, T.B.; Harlow, S.P.; Weaver, D.L.; Ashikaga, T.; Bryant, J.; Single, R.M.; Wolmark, N. NSABP-32: Phase III, randomized trial comparing axillary resection with sentinel lymph node dissection: A description of the trial. Ann. Surg. Oncol. 2004, 11, 208S-210S.
25. Chagpar, A.B.; Martin, R.C.; Scoggins, C.R.; Carlson, D.J.; Laidley, A.L.; El-Eid, S.E.; McGlothin, T.Q.; Noyes, R.D.; Ley, P.B.; Tuttle, T.M.; et al. Factors predicting failure to identify a sentinel lymph node in breast cancer. Surgery 2005, 138, 56-63.
26. Martel, P.; Capdet, J.; Méry, E.; Zerdoud, S.; Ferron, G.; Rafii, A.; Roché, H.; Querleu, D. Critical study of our initial experience of 993 sentinel node biopsies for breast surgery. Bull. Cancer 2008, 95, 763-772.
27. Ramjeesingh, R.; Quan, M.L.; Gardner, S.; Holloway, C.M. Prediction of involvement of sentinel and nonsentinel lymph nodes in a Canadian population with breast cancer. Can. J. Surg. 2009, 52, 23-30.
28. Steeg, P.S.; Bevilacqua, G.; Kopper, L.; Thorgeirsson, U.P.; Talmadge, J.E.; Liotta, L.A.; Sobel, M.E. Evidence for a novel gene associated with low tumour metastatic potential. J. Natl. Cancer Inst. 1988, 80, 200-204.
29. Chen, S.L.; Wu, Y.S.; Shieh, H.Y.; Yen, C.C.; Shen, J.J.; Lin, K.H. p35 is a regulator of the metastasis suppressor gene nm23-H. Mol. Carcinog. 2003, 36, 204-214.
30. Martinez, J.A.; Prevot, S.; Nordlinger, B.; Nguyen, T.M.; Lacarriere, Y.; Munier, A.; Lascu, I.; Vaillant, J.C.; Capeau, J.; Lacombe, M.L. Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumor stages. Gut 1995, 37, 712-720.
31. Mao, H.; Liu, H.; Fu, X.; Fang, Z.; Abrams, J.; Worsham, M.J. Loss of nm23 expression predicts distal metastasis and poorer survival for breast cancer. Int. J. Oncol. 2001, 18, 387-391.
32. Hirayama, R.; Sawai, S.; Takagi, Y.; Mishima, Y.; Kimura, N.; Shimada, N.; Esaki, Y.; Kurashima, C.; Utsuyama, M.; Hirokawa, K. Positive relationship between expression of anti-metastatic factor (nm23 gene product or nucleoside diphosphate kinase) and good prognosis in human breast cancer. J. Natl. Cancer Inst. 1991, 83, 1249-1250.
33. Tokunaga, Y.; Urano, T.; Furukawea, K.; Kondo, H.; Kanematsu, T.; Shiku, H. Reduced expression of nm23/NDP kinase-h1, but not nm23/NDP kinase-h2, is concordant with the frequency of lymph-node metastasis of human breast cancer. Int. J. Cancer 1993, 55, 66-71.
34. Lee, J.H.; Miele, M.E.; Hicks, D.J.; Phillips, K.K.; Trent, J.M.; Weissman, B.E.; Welch, D.R. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J. Natl. Cancer Inst. 1996, 88, 1731-1737.
35. Lee, J.H.; Welch, D.R. Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1. Cancer Res. 1997, 57, 2384-2387.
36. Mitchell, D.C.; Abdelrahim, M.; Weng, J.; Stafford, L.J.; Safe, S.; Bar-Eli, M.; Liu, M. Regulation of KiSS-1 metastasis suppressor gene expression in breast cancer cells by direct interaction of transcription factors activator protein-2alpha and specificity protein-1. J. Biol. Chem. 2006, 281, 51-58.
37. Kostadima, L.; Pentheroudakis, G.; Pavlidis, N.; The missing kiss of life: Transcriptional activity of the metastasis suppressor gene KiSS1 in early breast cancer. Anticancer Res. 2007, 27, 2499-2504.
38. Wada, N.; Imoto, S.; Yamauchi, C.; Hasebe, T.; Ochiai, A.; Predictors of tumor involvement in remaining axillary lymph nodes of breast cancer patients with positive sentinel lymph node. Eur. J. Surg. Oncol. 2006, 32, 29-33.
39. Cutuli, B.; Velten, M.; Martin, C. Assessment of axillary lymph node involvement in small breast cancer: Analysis of 893 cases. Clin. Breast Cancer 2001, 2, 59-65.
40. Chu, K.U.; Turner, R.R.; Hansen, N.M.; Brennan, M.B.; Bilchik, A.; Giuliano, A.E. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann. Surg. 1999, 229, 536-541.
41. Henderson, I.C.; Patek, A.J. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res. Treat. 1998, 52, 261-288.
42. Nouh, M.A.; Ismail, H.; El-Din, N.H.; El-Bolkainy, M.N. Lymph node metastasis in breast carcinoma: Clinicopathological correlations in 3747 patients. J. Egypt. Natl. Cancer Inst. 2004, 16, 50-56.
43. Cetintaş, S.K.; Kurt, M.; Ozkan, L.; Engin, K.; Gökgöz, S.; Taşdelen, I. Factors influencing axillary node metastasis in breast cancer. Tumori 2006, 92, 416-422.
44. Anderson, W.F.; Katki, H.A.; Rosenberg, P.S. Incidence of breast cancer in the United States: Current and future trends. J. Natl. Cancer Inst. 2011, 103, 1397-402.
45. Ravdin, P.M.; de Laurentiis, M.; Vendely, T.; Clark, G.M. Prediction of axillary lympth node status in breast cancer patients by use of prognostic indicators. J. Natl. Cancer Inst. 1994, 86, 1171-1175.
46. Gann, P.H.; Colilla, S.A.; Gapstur, S.M.; Winchester, D.J.; Winchester, D.P. Factors associated with axillary lymph node metastasis from breast carcinoma: Descriptive and predictive analyses. Cancer 1999, 86, 1511-1519.
47. Viale, G.; Zurrida, S.; Maiorano, E.; Mazzarol, G.; Pruneri, G.; Paganelli, G.; Maisonneuve, P.; Veronesi, U. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer 2005, 103, 492-500.
48. Kastner, P.; Krust, A.; Turcotte, B.; Stropp, U.; Tora, L.; Gronemeyer, H.; Chambon, P. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990, 9, 1603-1614.
49. Hopp, T.A.; Weiss, H.L.; Hilsenbeck, S.G.; Cui, Y.; Allred, D.C.; Horwitz, K.B.; Fuqua, S.A. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin. Cancer Res. 2004, 10, 2751-2760.